Affinia Therapeutics to Present Data on Novel Cardiotropic and BBB-Penetrant AAV Capsids and Preclinical Efficacy and Safety in Genetic Cardiomyopathies and Sporadic ALS at the American Society of Gene & Cell Therapy 2024 Annual Meeting
Affinia Therapeutics announced that new preclinical data on its novel AAV capsids for genetic cardiomyopathies and diseases of the central nervous system such as amyotrophic lateral sclerosis, as well as the Company’s high-yield manufacturing process, will be presented in several oral and poster sessions at the American Society of Gene and Cell Therapy 2024 Annual Meeting, being held May 7-11, 2024 in Baltimore, MD and virtually.